An interim trial analysis for Oxford-AstraZeneca's COVID-19 vaccine found the candidate's average efficacy to be 70 percent. While considered encouraging, it falls short of the rates shown by Pfizer/BioNTech and Moderna, whose vaccines appear to be more than 90 percent effective.
Still, the Oxford-AstraZeneca candidate has a few key advantages — it can be stored at regular refrigerators temperatures for a long period of time, and it's much cheaper than the other candidates, which means it could be particularly crucial for developing nations and rural communities around the world.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
‘Congratulations on your house, but maybe try a greyhound instead’Instant Opinion Opinion, comment and editorials of the day
-
How climate change poses a national security threatThe explainer A global problem causing more global problems
-
The 5 best TV shows about the mobThe Week Recommends From the show that launched TV’s golden age to a Batman spin-off, viewers can’t get enough of these magnificent mobsters
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
